Prospective cohort study of optimal discontinuation of oxaliplatin in elderly patients treated with XELOX plus bevacizumab
Ontology highlight
ABSTRACT: Interventions: XELOX+BEV Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Bevacizumab:7.5mg/kg d1 Q3w Discontinuation of oxaliplatin when neurotoxicity develops >=Grade2
Primary outcome(s): Rate of Grade3 neuropathy
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2631347 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA